VivoSeq
Musculoskeletal

Frozen Shoulder

23

Pipeline Programs

7

Active Trials

14

Companies Involved

Frozen Shoulder is an emerging landscape with 23 programs across 14 companies. The most active players are Endo Pharmaceuticals, Matrizyme Pharma Corporation, Amphastar Pharmaceuticals, Inc.. 9 therapies are approved with 2 more in late-stage development.

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

19/100

Mech. Concentration

43/100

Completion Rate

77/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

88%

Small molecule

29 of 33 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody26%Protein / enzyme26%

Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 94% of 36 pipeline programs.

Trial Status

24

clinical trials

Completed10 · 42%
Recruiting5 · 21%
Unknown status4 · 17%
Terminated2 · 8%
Not yet recruiting2 · 8%
Withdrawn1 · 4%

Trial Activity

24 trials

Prolotherapy Intervention in Patient With Frozen Shoulder
Completed··Phase 4·NCT05131269·32 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)